134 related articles for article (PubMed ID: 16954551)
1. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Mavi A; Urhan M; Yu JQ; Zhuang H; Houseni M; Cermik TF; Thiruvenkatasamy D; Czerniecki B; Schnall M; Alavi A
J Nucl Med; 2006 Sep; 47(9):1440-6. PubMed ID: 16954551
[TBL] [Abstract][Full Text] [Related]
2. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
4. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
[TBL] [Abstract][Full Text] [Related]
5. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
7. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
8. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
[No Abstract] [Full Text] [Related]
9. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
10. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
11. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
12. The effect of age, menopausal state, and breast density on (18)F-FDG uptake in normal glandular breast tissue.
Mavi A; Cermik TF; Urhan M; Puskulcu H; Basu S; Cucchiara AJ; Yu JQ; Alavi A
J Nucl Med; 2010 Mar; 51(3):347-52. PubMed ID: 20150253
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes in breast cancer on dual-time-point
Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
[TBL] [Abstract][Full Text] [Related]
14. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT.
Razak HR; Geso M; Abdul Rahim N; Nordin AJ
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):556-62. PubMed ID: 22141602
[TBL] [Abstract][Full Text] [Related]
15. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
18. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
[TBL] [Abstract][Full Text] [Related]
19. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
20. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
